Management of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

Diagnosis and Initial Management

A patient with a wide complex irregular tachycardia should be assumed to have preexcited atrial fibrillation due to Wolff-Parkinson-White syndrome until proven otherwise, and should be treated with procainamide or ibutilide as first-line pharmacological therapy, according to the European Heart Journal 1, 2, 3
The presentation of a wide QRS complex (≥120 ms) and irregular rhythm is highly suggestive of preexcited atrial fibrillation in the context of Wolff-Parkinson-White syndrome, as the irregularity indicates chaotic atrial conduction with variable ventricular response through the accessory pathway, and the wide QRS complex reflects anterograde conduction down the accessory pathway, which bypasses the AV node 1, 2
This presentation carries a risk of degenerating into ventricular fibrillation if managed incorrectly, as the accessory pathway can conduct rapidly and precipitate ventricular fibrillation 1, 4

Procainamide intravenous or ibutilide are recommended as first-line treatment (Class I) for patients with preexcited atrial fibrillation, according to the European Heart Journal and the Journal of the American College of Cardiology 1, 2, 3
The American College of Cardiology recommends procainamide or ibutilide as first-line therapy for preexcited atrial fibrillation, with a strength of evidence of Class I 3
Alternative pharmacological options (Class IIb) include quinidine, disopyramide, and amiodarone (with caution), although amiodarone can accelerate ventricular conduction in Wolff-Parkinson-White syndrome and should be used with extreme caution 6, 1, 2, 3

The European Heart Journal and the Journal of the American College of Cardiology recommend that the following medications be avoided in preexcited atrial fibrillation (Class III): AV nodal blockers, including digoxin, diltiazem, verapamil, and beta-blockers, as they can precipitate ventricular fibrillation by prolonging the AV nodal refractory period and favoring conduction down the accessory pathway 6, 1, 2, 3, 5

The European Heart Journal and the Journal of the American College of Cardiology recommend cardioversion for patients with preexcited atrial fibrillation who develop hemodynamic instability, or for those who fail pharmacological therapy, with a strength of evidence of Class I 1, 2, 3
Catheter ablation of the accessory pathway is recommended (Class I) for all symptomatic patients with Wolff-Parkinson-White syndrome who present with atrial fibrillation, with a success rate of 93-98.5%, according to the Journal of the American College of Cardiology and Praxis Medical Insights 1, 2, 3, 5, 7